Automated Insulin Delivery in Diabetic Pregnancy Faces Landmark Global Evidence Review

Pregnancy with type 1 diabetes is one of the most unforgiving proving grounds in modern medicine. For nine months, blood glucose targets sit in a band far narrower than anything demanded of non-pregnant adults, insulin requirements swing dramatically as the fetus grows, and every treatment decision carries consequences for two patients at once. Now, a research team has published a detailed protocol for what promises to be the most comprehensive synthesis yet of commercial automated insulin delivery systems in this setting, aiming to answer not only whether these devices work, but for whom, under what conditions, and at what practical cost.

The protocol, published in Health Science Reports and registered with the international PROSPERO registry, describes a mixed-methods systematic review and meta-analysis that will pull together randomised trials, real-world cohort studies, qualitative interviews and implementation research on hybrid closed-loop systems such as CamAPS FX, Medtronic MiniMed platforms, Tandem Control-IQ and Omnipod 5. What makes the effort timely is the sheer speed of adoption. In England and Wales, the 2025 National Pregnancy in Diabetes Audit recorded that nearly 45 percent of women with type 1 diabetes at 28 weeks of pregnancy were using the CamAPS FX closed-loop system, with another 12 percent on a different hybrid platform. Yet that figure comes from a single publicly funded health system, and the researchers caution it cannot be extrapolated to countries where reimbursement, regulatory approval and clinical workforce differ wildly.

The stakes are high because type 1 diabetes in pregnancy remains stubbornly dangerous despite decades of specialist care. Women with the condition face elevated risks of pre-eclampsia, preterm birth, caesarean delivery, excessively large babies, neonatal hypoglycaemia and admission of their newborns to intensive care. The mothers themselves risk severe hypoglycaemia, diabetic ketoacidosis and progression of retinal and kidney damage. Large national audits continue to report worse outcomes than in the general obstetric population, even as technology use climbs. The core problem is physiological: insulin sensitivity shifts across gestation, glucose variability increases, and the relentless self-management burden falls on women, families and care teams already stretched thin.

Continuous glucose monitoring has transformed how clinicians measure that burden. The metric at the heart of the new review is time in range, specifically the pregnancy-specific target of 3.5 to 7.8 millimoles per litre, a window far tighter than the standard adult range. Landmark studies such as CONCEPTT and subsequent large cohort analyses established that more time in this range and less glucose variability translate directly into fewer large-for-gestational-age births, fewer hypoglycaemic newborns and fewer intensive care admissions. But even sensor-augmented pumps and monitored injection regimens still depend heavily on users and clinicians manually adjusting insulin doses, leaving dangerous highs and lows to persist precisely when insulin requirements are changing fastest.

Automated insulin delivery systems promise to close that gap. These platforms couple a glucose sensor, an insulin pump and an embedded algorithm that continuously modulates insulin delivery in response to sensor readings, adjusting basal rates and, in some systems, delivering automated correction doses. In non-pregnant populations, trials and meta-analyses show such systems increase time in range and reduce time spent dangerously low without clear increases in severe hypoglycaemia or ketoacidosis. Pregnancy, however, is not simply an extension of ordinary type 1 diabetes care. Many commercial algorithms were never designed around pregnancy-specific glucose targets, raising unresolved questions about device suitability, target settings, the best timing for initiation, clinician oversight, use during labour and adaptation to rapidly shifting insulin needs.

The clinical evidence so far is promising but fragmented. Randomised trials including AiDAPT, which tested CamAPS FX, and CRISTAL, which evaluated the MiniMed 780G, have reported improved glycaemic outcomes in selected settings, but they differ in device, comparator, algorithm targets, timing of initiation and support models. Observational cohorts and case series add real-world texture but vary enormously in size, baseline technology use and outcome definitions. The protocol’s authors argue that commercial automated insulin delivery in pregnancy must not be treated as a single homogeneous intervention; the meaning of any pooled result depends on which system was used, when it was started, how it was supported and which outcomes were measured.

That heterogeneity shapes the review’s unusually rigorous methodology. The team will not pool randomised and non-randomised studies together, and pairwise meta-analyses will be run separately for each comparator: closed-loop versus sensor-augmented pump therapy, versus monitored multiple daily injections, and versus clearly defined usual care. The primary outcome, pregnancy-specific time in range, will be harmonised by prioritising second-trimester estimates, with third- and first-trimester values used in descending order of preference. Network meta-analysis is deliberately not planned, because differences in devices, populations, timing and care models could violate the statistical assumptions such analyses require. Rare events such as diabetic ketoacidosis, severe hypoglycaemia and perinatal mortality will be handled with sparse-data methods or synthesised narratively when estimates are unstable.

What truly distinguishes the protocol is its breadth beyond glucose numbers. The review will capture maternal outcomes including hypertensive disorders, retinopathy progression and mode of delivery; neonatal outcomes from birthweight centiles to intensive care admission; and early postpartum outcomes grouped into the first 48 hours, the first two weeks after discharge and out to 12 weeks, a period when breastfeeding, sleep disruption and collapsing insulin requirements create new hazards. Psychosocial measures, including diabetes distress, fear of hypoglycaemia, sleep quality, anxiety and depression, will be extracted with full attention to instrument validation. Crucially, qualitative studies of women’s and clinicians’ lived experiences will be synthesised thematically and then integrated with the quantitative findings through structured side-by-side comparison, so that numbers can be explained, contextualised or challenged by human experience.

Implementation realities also take centre stage. The review will document device and consumable costs, reimbursement arrangements, out-of-pocket expenses, clinician workload, training demands, uptake and retention rates, and reported barriers to equitable access, always tied to the specific jurisdiction and regulatory context of each study. The authors are explicit that access, equity and workload will be treated as descriptive domains, with causal claims made only where study designs genuinely support them. Certainty in the quantitative evidence will be graded using the GRADE framework, while confidence in qualitative findings will be assessed with GRADE-CERQual, allowing the two evidence streams to be weighed on their own terms.

The anticipated limitations are candidly acknowledged: likely few randomised trials, inconsistent definitions for neonatal hypoglycaemia and device-related adverse events, off-label use of systems with non-pregnancy-specific settings, and qualitative evidence skewed toward specialist early-adopter centres. Yet the strengths are substantial, including prospective registration, alignment with PRISMA-P reporting standards, no language restrictions on searches extending back to 2010, and dual independent screening and appraisal at every stage. When the completed review arrives, it should give clinicians, guideline developers and health services something the field currently lacks: a clear, device-specific, globally honest account of whether automated insulin delivery improves diabetic pregnancies, and what it takes, technically, financially and organisationally, to deliver that benefit safely and equitably.

Subject of Research: A mixed-methods systematic review protocol evaluating commercial automated insulin delivery systems in type 1 diabetes pregnancy

Article Title: Commercial Automated Insulin Delivery Systems in Type 1 Diabetes Pregnancy: Protocol for a Mixed‐Methods Systematic Review and Meta‐Analysis of Glycaemic, Perinatal, Psychosocial and Implementation Outcomes

Article References: Li, J., Sheklabadi, E., Goldstein, R. F., Ng, A. H., Teede, H., & Naderpoor, N. (2026). Commercial Automated Insulin Delivery Systems in Type 1 Diabetes Pregnancy: Protocol for a Mixed‐Methods Systematic Review and Meta‐Analysis of Glycaemic, Perinatal, Psychosocial and Implementation Outcomes. Endocrinology, Diabetes & Metabolism, 9(5), Article e70309. https://doi.org/10.1002/edm2.70309

Image Credits: AI Generated

DOI: 10.1002/edm2.70309

Keywords: type 1 diabetes, pregnancy, automated insulin delivery, hybrid closed-loop, continuous glucose monitoring, time in range, perinatal outcomes, CamAPS FX, systematic review, meta-analysis, health technology, implementation science